234 results about "Metabolic enzymes" patented technology

Microneedle devices are provided for controlled sampling of biological fluids in a minimally-invasive, painless, and convenient manner. The microneedle devices permit in vivo sensing or withdrawal of biological fluids from the body, particularly from or through the skin or other tissue barriers, with minimal or no damage, pain, or irritation to the tissue. The microneedle device includes one or more microneedles, preferably in a three-dimensional array, a substrate to which the microneedles are connected, and at least one collection chamber and / or sensor in communication with the microneedles. Preferred embodiments further include a means for inducing biological fluid to be drawn through the microneedles and into the collection chamber for analysis. In a preferred embodiment, this induction is accomplished by use of a pressure gradient, which can be created for example by selectively increasing the interior volume of the collection chamber, which includes an elastic or movable portion engaged to a rigid base. Preferred biological fluids for withdrawal and / or sensing include blood, lymph, interstitial fluid, and intracellular fluid. Examples of analytes in the biological fluid to be measured include glucose, cholesterol, bilirubin, creatine, metabolic enzymes, hemoglobin, heparin, clotting factors, uric acid, carcinoembryonic antigen or other tumor antigens, reproductive hormones, oxygen, pH, alcohol, tobacco metabolites, and illegal drugs.

The present invention provides Listeria vaccine strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.

This invention relates to a peptide or protein capable of converting a transcription factor into a transcriptional repressor, a gene encoding such peptide or protein, a chimeric protein in which the aforementioned peptide or protein is fused to a transcription factor, a chimeric gene in which the gene encoding a peptide or protein is fused to a gene encoding a transcription factor, a recombinant vector having such chimeric gene, and a transformant comprising such recombinant vector. The peptide of the invention that is capable of converting a transcription factor into a transcriptional repressor is very short. Thus, it can be very easily synthesized, and it can effectively and selectively repress the transcription of a specific gene. Accordingly, such gene is applicable to and useful in a wide variety of fields, such as repression of the expression of cancerous genes and regulation of the expression of genes encoding pigment-metabolic enzymes.

The present invention provides Listeria strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.

The invention discloses an oxadiazole-contained cyclic compound, a preparation method, intermediates, compositions and application thereof. The medically acceptable salts, the enantiomer, the diastereoisomer, the tautomer, the solvate, the metabolite or the prodrug of the dthe oxadiazole-contained cyclic compound shown as the formula I is high in inhibitory activity on IDO (dioxygenase) at a molecular level and a cellular level and significant in proliferation inhibition effects on cancer cells related to IDO activity at an animal level and good in liver microsome stability of human, mouse andthe like, has no significant inhibition over metabolic enzymes and achieves good absorption properties and high bioavailability in rats and mice as well as good druggability.

The present invention provides Listeria strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.

The invention provides a method for obtaining race specific loci and a race inference system and application thereof. The method comprises the following steps: selecting black, white and yellow race groups; obtaining SNP loci in genomes of the black, white and yellow race groups; selecting the SNP loci in pigmentation genes and xenobiotic metabolic enzyme genes of the black, white and yellow racegroups; screening the ancestor information marker loci of the black, white and yellow race groups from the selected SNP loci; and screening the specific loci of the black, white and yellow races fromthe ancestor information marker loci. The screened specific loci of the black, white and yellow races are integrated, thus obtaining the black, white and yellow race inference system which can be used for carrying out black, white and yellow race origin inference of the individual with unknown origin accurately and efficiently.

The present invention provides Listeria strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.

The invention discloses a rapid screening method for comprehensively evaluating the in-vitro inhibitory effect of nine human liver CYP450 metabolic enzymes by utilizing 14 probe substrates and 16 probe reaction. The invention mainly relates to a method for monitoring metabolic activity variation of 9 human liver CYP450 enzymes and rapidly and comprehensively evaluating an inhibitory effect of a tested compound on the metabolic enzyme by adopting an in-vitro mixed probe incubation method and LC / MS / MS. According to the method, the exclusiveness and diversity of the probe substrate, interaction of the probe substrates, influence of different inoculation conditions (by charging organic solvent, buffer solution and BSA) in a warm inoculation system and the enzyme kinetics characteristics of 16 probe reactions under the selected inoculation condition are comprehensively considered, a brand new in-vitro system is established by integrating high-sensitive and high-selective LC-MS / MS technology, so that the inhibitory effect of the tested compounds on the nine human liver main metabolic enzymes can be more accurately and comprehensively predicted in the high-throughput screening of the novel drug development, and the predictability on the interaction of the later metabolism can be improved.

A composite active mycelium feed without environmental pollution for improving immunity of animal and fowl and the quality of meat, egg, or milk, preventing diseases, and decreasing the foul smell of droppings or dung is prepared from the straw, stalk, or weeds through treating by fungus and useful bacteria. It is rich in nutrients including physiologically active substance, digestive enzymes, metabolic enzymes, mycopolyose, cellulose, amino acids, trace elements, etc.

The invention discloses a nimodipine capsule with high dissolution and semi-solid composition as content and a preparation method thereof, and belongs to the pharmaceutical preparation field. The method comprises the following steps of mixing micronized nimodipine and a hydrophilic carrier, preparing into solid dispersion by melting extrusion method, cooling, pulverizing, mixing with semi-solid matrix, surfactant, melting point regulator under heating, and filling the content into hard capsule with a capsule filling machine. The invention combines the melting extrusion technique and semi-solid filling hard capsule technique, and after the prepared novel nimodipine capsule is administered into human body, the nimodipine quickly diffuses in molecular form and saturates metabolic enzymes, so as to improve bioavailability. The inventive nimodipine capsule solves the low dissolution and low utilization ratio problems of prior nimodipine preparation; and has the advantages of high dissolution, good stability, simple preparation method, and applicability to industrial production.

The invention discloses a composite essential oil antistaling agent, which comprises the following components based on a total amount of 100 parts by weight: 0.15-0.25 parts by weight of lemongrass essential oil, 0.02-0.1 part by weight of clove essential oil, and 0.02-0.1 part by weight of cinnamon essential oil , 0.07-0.15 parts by weight of rapeseed essential oil, 0.14-0.26 parts by weight of thyme essential oil, 0.25-0.4 parts by weight of tea tree essential oil, 0.05-0.15 parts by weight of sodium carboxymethyl inulin, 0.32-0.68 parts by weight of water-soluble chitosan, 0.5-0.8 parts by weight of stearic acid, and the balance is deionized water. The present invention uses lemongrass essential oil, clove essential oil, cinnamon essential oil, rapeseed essential oil, thyme essential oil, tea tree essential oil and other raw materials to prepare the preservative. The activity of various metabolic enzymes, thereby weakening the impact of microbial activities on the surface of the peel, delaying the physiological activities of the fruit, thereby maintaining the effect of fruit freshness.

The invention discloses application of miR-375-3p in prevention and treatment of lepidoptera pests. According to the application, prodenia litura which are agricultural pests are adopted to do an experiment which shows that Sl-miR-375-3p affects intake of polypide due to suppression of the expression of detoxifying enzymes and metabolizing enzymes which are required for digestion of food in the polypide, and finally thinness and smallness and even death of the polypide are caused. The prodenia litura miR-375-3p can be used for preventing and treating pests of any lepidoptera insects; by the same reasoning, the miR-375-3p of any lepidoptera pests can be used for preventing and treating the pests of the same type of other insects. The miR-375-3p of the insects can be used for preparing an insecticide or preventing and treating the pests of transgenic plants expressing the miR-375-3p.

Therapeutic compounds having increased resistance to deamination and inactivation by metabolic enzymes are provided. The compounds include nucleotide analogs and nucleotide analogs, derivatized with aminal and / or thioaminal groups to prevent deamination of free amine. The compounds can be used in a variety of treatments, including treatment of neoplastic disorders, infections from fungal or fungal-like organisms, and infections from parasites.

The invention provides a kit for quantitatively detecting niacin, nicotinamide and pantothenic acid in peripheral whole blood at the same time, which mainly consists of dried blood slices (Whatman protein saver 903), capillary blood collection tubes, nicotinic acid and nicotinamide and pantothenic acid vitamin standard substance and its isotope internal standard, trichloroacetic acid, and also includes dry blood spot preparation, dry blood spot pretreatment and detection steps. The nicotinic acid, nicotinamide, and pantothenic acid dry blood spot quantitative kit provided by the present invention combines dry blood spot sampling technology with high performance liquid chromatography-tandem mass spectrometry technology for the quantification of B vitamins, a minimally invasive, minimal blood collection at the same time Realize the evaluation of the nutritional status of multiple B vitamins, and realize the quantitative work of simultaneous detection of multiple vitamins under low sample volume conditions that cannot be accomplished by metabolic enzyme-dependent methods and immunoassay methods.

The invention discloses an Si-substrate medium / long wave laminated bicolor HgCdTe material and a preparation method thereof. The method comprises the steps of cleaning an epitaxial-level Si substrate, removing an autoxidation layer of the Si substrate, forming an artificial oxidation layer, removing the oxidation layer of the Si substrate, conducting As passivation, allowing a ZnTe buffer layer to grow through transfer enhancement MME (melanin metabolic enzyme), allowing a CdTe buffer layer to grow, and allowing three HgCdTe thin layers with different components and thicknesses to grow.

An object of the present invention is to provide a method for producing ethanol efficiently even in the presence of a fermentation inhibitor in a saccharified biomass. The present invention provides a method for producing ethanol from biomass, comprising: culturing a transformed xylose-utilizing yeast to overexpress the gene for at least one pentose phosphate pathway metabolic enzyme, with a saccharified biomass.

The invention provides an epilepsy medication recommendation method and system, and belongs to the technical field of biomedicine and data processing. According to the invention, deep sequencing is carried out on an antiepileptic drug metabolic enzyme gene, a transporter gene and a drug action target gene, related coding gene polymorphic sites are screened, a Bayesian accumulation regression treemodel and random forest regression are utilized to obtain a personalized medication scheme depending on individual genes, and a subset with high treatment effect is identified, so that clinical medication is guided in a targeted manner, the epilepsy control rate is improved, adverse reactions are reduced, the time for doctors and patients to explore the optimal treatment scheme is shortened, the diagnosis and treatment efficiency is improved, and the method has good practical application value.

Targeting metabolic enzymes in human cancer Abstract Lung cancer is a devastating disease and a major therapeutic burden with poor prognosis. The functional heterogeneity of lung cancer (different tumor formation ability in bulk of tumor) is highly related with clinical chemoresistance and relapse. Here we find that, glycine dehydrogenase (GLDC), one of the metabolic enzyme involved in glycine metabolism, is overexpressed in various subtypes of human lung cancer and possibly several other types of cancers. GLDC was found to be highly expressed in tumor-initiating subpopulation of human lung cancer cells compared with non-tumorigenic subpopulation. By array studies we showed that normal lung cells express low levels of GLDC compared to xenograft and primary tumor. Functional studies showed that RNAi inhibition of GLDC inhibits significantly the clonal growth of tumor-initiating cells in vitro and tumor formation in immunodeficient mice. Overexpression of GLDC in non-tumorigenic subpopulation convert the cells to become tumorigenic. Furthermore, over-expression of GLDC in NIH / 3T3 cells and human primary lung fibroblasts can transform these cells, displaying anchorage-independent growth in soft agar and tumor-forming in mice. Not only is GLDC is expressed human lung cancer, it is also up-regulated in other types of cancer, such as colon cancer. RNAi knockdown of GLDC in colon cancer cell line, CACO-2 cells, can also inhibit the tumor formation in mice. Thus GLDC maybe a new metabolic target for treatment of lung cancer, and other cancers.

The present invention provides Listeria vaccine strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.

The invention provides specificity probe zymolyte of glucuronic acid transferase UGT1A1 and application. The specificity probe zymolyte includes dihydro flavonoids compounds of C-4' hydroxyl. Procedures of enzymatic determination are that C-4' hydroxyl-glucose aldehyde acid of bavachinin is selected to be metabolized to a probe reaction. Activity of UGT1A1 enzyme of each biological sample, cell, in vivo and whole organ is measured by quantitative determining of removing quantity of fructus psoraleae flavanone methyl ether in unit time or generation quantity of glucose aldehyde acidize metabolite of the fructus psoraleae flavanone methyl ether. The specificity probe zymolyte of glucuronic acid transferase UGT1A1 can be used for quantitative evaluating of the activity of the UGT1A1 enzyme of different species, different individual source biology samples and quantitative evaluating of the activity of the UGT1A1 enzyme of animal tissue cell culture fluid of different sources and cell prepared products so as to assess ability of handling drugs on important drug metabolic enzyme UGT1A1.

The invention relates to the technical field of medicine, in particular to a novel chemical restructuring high-density lipoprotein structure, which is used as an anti-tumor drug carrier and is characterized by improving stability of a restructuring high-density lipoprotein carrier under the action of metabolic enzymes, blocking nutrient substances required by multiplication of tumor cells by utilizing the role that high-density lipoprotein transfers the drug in a targeted mode to gland tumor cells and the role that mediate cholesterol flows out, and improving toxic effect of the anti-tumor drug on tumor cells.

The invention relates to a botanical drug compound recipe for preventing and treating microwave radiation injury. According to the invention, it is found that botanical drugs mainly consisting of peony root, milkvetch root, duckweed and red sage root can be used for preparing a medicine used for preventing and treating microwave radiation injury. According to results of abundant experiments of detection of learning and memory capacity of rats, hippocampal amino acid neurotransmitters, sperm motility, the rate of teratosperm, myocardial metabolic enzyme (CK-MB, LDH and AST activity) and the content of Ca<2+> in serum of rats, the number of peripheral blood lymphocytes and the like, the medicine provided in the invention has an obvious treatment effect on injury to the brain, reproduction, the heart and immunity of rats caused by microwave radiation, and the effect is superior to that of medicines on the market.

The invention belongs to the field of traditional Chinese medicine manufacturing, and relates to application of leonurine to preparation of a medicament for treating 2-type diabetes. Animal experiments prove that the fasting blood glucose of a 2-type diabetes mouse, i.e., a db / db mouse, can be lowered by the leonurine, and the tolerance of oral glucose is improved; and meanwhile, fasting plasma insulin is increased, the plasma triglyceride is reduced and the content of the plasma high-density lipoprotein is increased. Experiment results also show that the expression of liver glucose metabolic enzymes such as glucokinase, glucose-6-phosphatase and phosphoenolpyruvate carboxyl enzyme is adjusted by the leonurine in an Akt dependent mode; and the biological response of an inflammatory mediator, such as generation of TNF (Tumor Necrosis Factor)-alpha, degradation of IkB-alpha and subsequent phosphorylation of NF-kBp65, is suppressed. Through the leonurine, the inflammatory state of the 2-type diabetes can be corrected, and the symptoms of the 2-type diabetes can be improved; and the leonurine can be used as a treatment medicament to be applied to the treatment of the 2-type diabetes.

This invention discloses the first cellular acetylated substrate protein of SIRT3, Acetyl-CoA synthetase 2 (AceCS2), which is a mitochondrial matrix protein. AceCS2 is reversibly acetylated at lysine 642 (Lys642) in the active site of the enzyme. The mitochondrial sirtuin SIRT3 interacts with AceCS2 and deacetylates Lys642 both in vitro and in vivo. Deacetylation of AceCS2 by SIRT3 activates the acetyl-CoA synthetase activity of AceCS2. Thus, a mammalian sirtuin directly controls the activity of a metabolic enzyme via reversible lysine acetylation. Modulators of the acetylation status or the activity of AceCS2 are useful for the treatment of pathological conditions, such as type II diabetes, hypercholesterolemia, hyperlipidemia, and obesity.

The invention discloses a tinidazole nano-composite silver micro-emulsified antibiotics, 0.10 to 1.50 units of tinidazole and 0.008 to 0.020 units of nano-silver being regarded as medical components, and 96.92 to 99.67 units of micro-emulsified substrate and 0.30 to 3.00 units of auxiliary materials are evenly mixed together with a certain percentage, then the tinidazole complex nano-silver micro-emulsified antibiotics can be got which has a yellow outlook, the diameter of grains is 1nm to 100nm, the invention is stable, which can not only disturb the synthesis of DNA, but also be able to combine with oxygen metabolic enzyme (-SH) to interrupt the respiration metabolism process, so as to kill the aerobic and anaerobic pathogens and improve the recovery of wounds, and diseases such as vaginitis, endometritis can be quickly and effectively cured, and the preparation method of the invention is simple and safe.